JP2017002041A5 - - Google Patents

Download PDF

Info

Publication number
JP2017002041A5
JP2017002041A5 JP2016114709A JP2016114709A JP2017002041A5 JP 2017002041 A5 JP2017002041 A5 JP 2017002041A5 JP 2016114709 A JP2016114709 A JP 2016114709A JP 2016114709 A JP2016114709 A JP 2016114709A JP 2017002041 A5 JP2017002041 A5 JP 2017002041A5
Authority
JP
Japan
Prior art keywords
igg antibody
recombinant igg
composition
antibody
sialylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016114709A
Other languages
English (en)
Japanese (ja)
Other versions
JP6322849B2 (ja
JP2017002041A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017002041A publication Critical patent/JP2017002041A/ja
Publication of JP2017002041A5 publication Critical patent/JP2017002041A5/ja
Application granted granted Critical
Publication of JP6322849B2 publication Critical patent/JP6322849B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016114709A 2006-04-05 2016-06-08 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 Expired - Fee Related JP6322849B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78938406P 2006-04-05 2006-04-05
US60/789,384 2006-04-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009504279A Division JP6084761B2 (ja) 2006-04-05 2007-04-03 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018053298A Division JP6686058B2 (ja) 2006-04-05 2018-03-20 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法

Publications (3)

Publication Number Publication Date
JP2017002041A JP2017002041A (ja) 2017-01-05
JP2017002041A5 true JP2017002041A5 (https=) 2017-06-15
JP6322849B2 JP6322849B2 (ja) 2018-05-16

Family

ID=38581601

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2009504279A Active JP6084761B2 (ja) 2006-04-05 2007-04-03 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2014182741A Pending JP2015038086A (ja) 2006-04-05 2014-09-08 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2016114709A Expired - Fee Related JP6322849B2 (ja) 2006-04-05 2016-06-08 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2018053298A Active JP6686058B2 (ja) 2006-04-05 2018-03-20 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2020065891A Expired - Fee Related JP6989979B2 (ja) 2006-04-05 2020-04-01 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2021192123A Active JP7357382B2 (ja) 2006-04-05 2021-11-26 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009504279A Active JP6084761B2 (ja) 2006-04-05 2007-04-03 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2014182741A Pending JP2015038086A (ja) 2006-04-05 2014-09-08 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018053298A Active JP6686058B2 (ja) 2006-04-05 2018-03-20 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2020065891A Expired - Fee Related JP6989979B2 (ja) 2006-04-05 2020-04-01 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2021192123A Active JP7357382B2 (ja) 2006-04-05 2021-11-26 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法

Country Status (12)

Country Link
US (14) US10167332B2 (https=)
EP (3) EP2010566B2 (https=)
JP (6) JP6084761B2 (https=)
CN (1) CN101432301B (https=)
AU (1) AU2007235413B2 (https=)
CA (1) CA2647524C (https=)
EA (1) EA022780B1 (https=)
IL (1) IL194526A (https=)
MX (1) MX2008012843A (https=)
NZ (1) NZ572379A (https=)
WO (1) WO2007117505A2 (https=)
ZA (1) ZA200808900B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2647524C (en) * 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011138354A1 (en) 2010-05-07 2011-11-10 Csl Behring Ag Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
JP5956982B2 (ja) 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
PT2793943T (pt) 2011-12-19 2018-11-13 Univ Rockefeller Polipéptidos anti-inflamatórios não siliados
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
CA2909139C (en) 2013-04-18 2021-07-06 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity
ES2802274T3 (es) * 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR20170040132A (ko) * 2014-06-02 2017-04-12 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 Fc 단편의 제조
EP3207055A1 (en) 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
EA038554B1 (ru) 2015-03-04 2021-09-14 Зе Рокфеллер Юниверсити Противовоспалительные полипептиды
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
EP3681908A1 (en) 2017-09-13 2020-07-22 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
CN117924477A (zh) 2017-12-19 2024-04-26 洛克菲勒大学 具有改进的效应子功能的人IgG Fc结构域变体
JP2021508479A (ja) 2017-12-27 2021-03-11 テネオバイオ， インコーポレイテッド ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
DK4257600T3 (da) 2018-07-03 2025-05-26 Gilead Sciences Inc Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
US20210347848A1 (en) 2018-08-31 2021-11-11 ALX Oncology Inc. Decoy polypeptides
SG11202102713TA (en) 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
US20210353752A1 (en) * 2018-10-11 2021-11-18 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
CN110297093B (zh) * 2019-03-18 2022-04-22 山西瑞豪生物科技有限公司 一种检测人免疫球蛋白g4的方法和试剂盒
KR102549282B1 (ko) * 2019-11-18 2023-06-30 건국대학교 산학협력단 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
CN115023441A (zh) 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
JP2025542423A (ja) * 2022-12-21 2025-12-25 コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション α－２，６－シアル化免疫グロブリンの眼球乾燥症または炎症性眼疾患の予防または治療用途
CN115819560A (zh) * 2022-12-27 2023-03-21 河南赛诺特生物技术有限公司 制备第二抗体的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2097617A1 (en) 1990-11-23 1992-05-23 Brian Seed Inhibition of cell adhesion protein-carbohydrate interactions
US5453272A (en) 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
HK1048138B (zh) * 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
DE19927835A1 (de) 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
CA2424977C (en) * 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
WO2002040047A2 (en) 2000-11-20 2002-05-23 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
MXPA05006522A (es) * 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
US20070048740A1 (en) 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP1670821A4 (en) 2003-10-09 2006-11-29 Daewoong Co Ltd PROCESS FOR PURIFYING HUMAN THROMBOPOIETIN WITH HIGH SIALIC ACID CONTENT
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005058244A2 (en) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
PT1896071E (pt) 2005-06-30 2015-07-09 Janssen Biotech Inc Métodos e composições com melhorias na atividade terapêutica
EP1937306B1 (en) 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2647524C (en) * 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ585530A (en) 2007-12-27 2012-06-29 Baxter Int Methods for differentiating plasma-derived protein from recombinant protein in a sample

Similar Documents

Publication Publication Date Title
JP2017002041A5 (https=)
FI3736291T3 (fi) Anti-fcrh5-vasta-aineita
HRP20250807T1 (hr) Protutijela koja vežu ljudski cgrp receptor
WO2014160463A8 (en) Prefusion rsv f proteins and their use
JP2011173914A5 (https=)
JP2016027050A5 (https=)
JP2014508759A5 (https=)
HRP20231579T1 (hr) Anti-ctla-4 antitijela i postupci njihove upotrebe
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
JP2014077000A5 (https=)
HRP20240182T1 (hr) Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
RU2014109038A (ru) Антитела к хондроитинсульфат протеогликану меланомы
JP2015533795A5 (https=)
JP2015522252A5 (https=)
RU2017104813A (ru) Молекулы со специфичностью к cd45 и cd79
RU2010120879A (ru) Антитела против g-белка распираторно-синцитиального вируса (rsv)
SG10201809694PA (en) Antibody neutralizing human respiratory syncytial virus
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
HRP20130204T1 (hr) Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže
BR112015022288A2 (pt) 2-aminopirimidin-6-onas e análogos exibindo atividades anticâncer e antiproliferativas, sua composição faramcêutica e seus usos
HRP20192052T1 (hr) Protutijela anti-siglec-8 te njihovi postupci i uporabe
HRP20170815T1 (hr) Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe
HRP20200767T1 (hr) Humanizirana anti-humana cd19 protutijela i postupci uporabe
JP2011137002A (ja) 組換えｉｌ−９抗体およびその使用